Welcome to our dedicated page for Perrigo news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo stock.
Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo (NYSE: PRGO) reported second quarter 2026 results from continuing operations, highlighting ongoing execution of its Three-S plan, portfolio simplification and debt reduction. All In reported net sales were $1.02 billion, down 3.2% year-over-year, while Core net sales declined 3.1% to $907 million. Organic All In net sales fell 1.3% and Core organic net sales declined 3.5%. Reported gross margin decreased to 30.7% and reported operating margin to 2.3%, mainly due to lower volumes, planned under absorption and unfavorable mix. Reported diluted EPS rose to $0.63, helped by the gain on the Dermacosmetics divestiture, while All In adjusted EPS declined to $0.50 and Core adjusted EPS to $0.46. Infant Formula net sales grew 23.1% with operating income improving, and the company applied most of the approximately $359 million Dermacosmetics proceeds to reduce debt, ending the quarter with $400 million in cash and $3.3 billion in total debt. Perrigo reaffirmed its full-year 2026 outlook, including All In adjusted EPS guidance of $2.00–$2.30 and Core adjusted EPS of $2.25–$2.55, and expects a sequentially stronger second half.
Perrigo (NYSE: PRGO) announced that its Board of Directors approved a quarterly cash dividend of $0.29 per share, equivalent to $1.16 per share on an annualized basis. The dividend is payable on September 15, 2026 to shareholders of record as of August 28, 2026.
Perrigo (NYSE: PRGO) announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will present at the Canaccord 46th Annual Growth Conference on Wednesday, August 12 at 10:30 AM EDT. The presentation will be webcast via the Perrigo investor relations website.
Perrigo describes itself as a leading pure-play self-care company focused on over-the-counter health and wellness products in North America and Europe, leveraging cash-generative store-brand private label offerings to invest in branded products such as Opill, Mederma, Compeed, EllaOne, and Jungle Formula.
Perrigo (NYSE: PRGO) plans to release its second quarter 2026 financial results on Wednesday, August 5, 2026, followed by a conference call at 8:30 a.m. EST hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra. The live earnings call will be accessible via webcast in Perrigo’s investor relations section and by telephone, with replay available from approximately 12:00 p.m. EST on August 5 through August 12, 2026.
Perrigo (NYSE: PRGO) announced the appointment of Salman Amin and Omer Gajial as independent directors to its Board, effective June 30, 2026.
Amin is a former CEO of pladis Global and senior leader at SC Johnson, PepsiCo, and Procter & Gamble. Gajial is CEO of GoTo Foods and former EVP and Chief Merchandising & Digital Officer at Albertsons Companies.
Perrigo (NYSE: PRGO) announced a leadership transition. Board member Albert A. Manzone was appointed Interim President and CEO, effective immediately, replacing Patrick Lockwood-Taylor, who resigned from his roles. The Board stated his personal conduct was inconsistent with the Code of Conduct but unrelated to business or financial reporting. Perrigo reaffirmed its full-year 2026 outlook, including All In net sales growth of (5.5)% to (1.5)%, All In adjusted EPS of $2.00–$2.30, Core net sales growth of (3.0)% to +1.0%, and Core adjusted EPS of $2.25–$2.55.
Perrigo (NYSE:PRGO) announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9, 2026, at 10:30 AM EDT.
The presentation webcast will be accessible via Perrigo's investor relations website.
Perrigo (NYSE: PRGO) reported first-quarter 2026 continuing-operations results. Core net sales were $842M, down 8.3% year-over-year (Core organic -11.0%). Reported diluted EPS was $(2.81) driven by a $330.8M goodwill impairment. Core adjusted operating margin was 12.8% and All In adjusted EPS was $0.43.
The company completed the post-quarter sale of its Dermacosmetics business with €305.6M upfront proceeds (up to €332.6M total) to support debt reduction, and reaffirmed full-year 2026 outlook with expected H2 improvement.
Perrigo (NYSE: PRGO) completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, consisting of €305.6 million upfront (including €5.6 million net working capital adjustment) and up to €27.0 million contingent over three years. Brands sold include ACO, Biodermal, Emolium, and Iwostin. Perrigo reported the divested unit had ~€120 million in 2025 net sales and represented ~5% of adjusted operating income. Perrigo said net proceeds will be used primarily to reduce debt and strengthen the balance sheet.
Perrigo (NYSE: PRGO) announced a quarterly cash dividend of $0.29 per share, equal to $1.16 annually. The dividend is payable on June 16, 2026 to shareholders of record on May 29, 2026. The release reiterates Perrigo's consumer health focus and investor relations contacts.